淀粉样神经病:从病理生理到轻链淀粉样变性和遗传性转甲状腺素蛋白淀粉样变性治疗的进展
本文综述淀粉样神经病的病理生理机制与治疗进展,涵盖轻链淀粉样变性和遗传性转甲状腺素蛋白淀粉样变性(ATTRv)。轻链淀粉样变性治疗因单克隆抗体和干细胞移植而革新,5年生存率提高至77%;新型基因治疗和转甲状腺素蛋白稳定剂改善了ATTRv神经病病程和生活质量,早期诊断和症状前检测至关重要。
要点
- 淀粉样神经病表现为长度依赖性感觉为主神经病伴全面性自主神经衰竭。
- 轻链淀粉样变性治疗因单克隆抗体和干细胞移植革新,5年生存率提高至77%。
- 新型基因治疗和转甲状腺素蛋白稳定剂改善ATTRv神经病病程和生活质量。
核心结论
- 轻链淀粉样变性治疗因单克隆抗体和干细胞移植革新,5年生存率提高至77%。
- 新型基因治疗和转甲状腺素蛋白稳定剂革新了ATTRv治疗,改善神经病病程(改良神经病损伤评分+7较基线变化更小)和生活质量。
- 随着淀粉样变性治疗重大进展,早期诊断和ATTRv家庭成员症状前检测已变得至关重要。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- 淀粉样神经病最常见于轻链淀粉样变性(克隆性非增殖性浆细胞病,免疫球蛋白轻链或重链片段沉积组织)和遗传性转甲状腺素蛋白淀粉样变性(ATTRv,常染色体显性TTR基因突变致蛋白易错折叠)。
- 淀粉样纤维沉积于周围神经内膜,常广泛累及背根神经节和交感神经节,导致邻近施万细胞萎缩和血-神经屏障破坏。
- 临床表现为长度依赖性感觉为主神经病伴全面性自主神经衰竭;早期发病Val30Met ATTRv早期显著累及无髓小神经,其他ATTRv和轻链淀粉样变性常累及大、小纤维。
- 神经传导检查、定量促汗轴突测试和表皮内神经纤维密度是评估去神经支配的有用工具。
- 组织活检(受累器官或替代部位)和骨亲和性放射性示踪剂心脏成像可证实淀粉样沉积。
临床怎么用
- 轻链淀粉样变性治疗因单克隆抗体和干细胞移植革新,5年生存率提高至77%。
- 新型基因治疗和转甲状腺素蛋白稳定剂革新了ATTRv治疗,改善神经病病程(改良神经病损伤评分+7较基线变化更小)和生活质量。
- 随着淀粉样变性治疗重大进展,早期诊断和ATTRv家庭成员症状前检测已变得至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Amyloid neuropathy is caused by deposition of insoluble β-pleated amyloid sheets in the peripheral nervous system. It is most common in: (1) light-chain amyloidosis, a clonal non-proliferative plasma cell disorder in which fragments of immunoglobulin, light or heavy chain, deposit in tissues, and (2) hereditary transthyretin (ATTRv) amyloidosis, a disorder caused by autosomal dominant mutations in the TTR gene resulting in mutated protein that has a higher tendency to misfold. Amyloid fibrils deposit in the endoneurium of peripheral nerves, often extensive in the dorsal root ganglia and sympathetic ganglia, leading to atrophy of Schwann cells in proximity to amyloid fibrils and blood-nerve barrier disruption. Clinically, amyloid neuropathy is manifested as a length-dependent sensory predominant neuropathy associated with generalized autonomic failure. Small unmyelinated nerves are involved early and prominently in early-onset Val30Met ATTRv, whereas other ATTRv and light-chain amyloidosis often present with large- and small-fiber involvement. Nerve conduction studies, quantitative sudomotor axon testing, and intraepidermal nerve fiber density are useful tools to evaluate denervation. Amyloid deposition can be demonstrated by tissue biopsy of the affected organ or surrogate site, as well as bone-avid radiotracer cardiac imaging. Treatment of light-chain amyloidosis has been revolutionized by monoclonal antibodies and stem cell transplantation with improved 5-year survival up to 77%. Novel gene therapy and transthyretin stabilizers have revolutionized treatment of ATTRv, improving the course of neuropathy (less change in the modified Neuropathy Impairment Score + 7 from baseline) and quality of life. With great progress in amyloidosis therapies, early diagnosis and presymptomatic testing for ATTRv family members has become paramount. ANN NEUROL 2024;96:423-440.
引用
- Chompoopong P, Mauermann ML, Siddiqi H, et al. Amyloid Neuropathy: From Pathophysiology to Treatment in Light-Chain Amyloidosis and Hereditary Transthyretin Amyloidosis. Ann Neurol. 2024. PMID: 38923548. doi:10.1002/ana.26965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。